ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO734

Urinary Extracellular Vesicles miR-143-3p: A Novel Candidate Biomarker for Preeclampsia

Session Information

Category: Women’s Health and Kidney Diseases

  • 2000 Women’s Health and Kidney Diseases

Authors

  • Suvakov, Sonja, Mayo Clinic, Rochester, Minnesota, United States
  • Jayachandran, Muthuvel, Mayo Clinic, Rochester, Minnesota, United States
  • Milic, Natasa, Medical Faculty University of Belgrade, Belgrade, Serbia
  • Garovic, Vesna D., Mayo Clinic, Rochester, Minnesota, United States
Background

Preeclampsia (PE) is a complex pregnancy-associated disorder which is characterized by new-onset hypertension and proteinuria (>300mg) after 20 weeks of gestation. Recent study from our group showed that number of podocytes-derived urinary extracellular vesicles (EVs) were increased in pregnant women with PE but their content of bioactive molecules are not known. Aim of this study was to assess differential expression of miRNAs in urinary EVs from pregnant women with and without PE.

Methods

Bio-banked cell-free urines from pregnant women with (n=5) and without (normotensive; n=5) PE were used for miRNA expression in urinary EVs. The expressions of miRNAs within urinary EVs were identified by XRNA Exosome RNA-Seq Library Kit. Validation of significantly changed candidate miRNAs between groups was performed by qPCR in the independent cohort of patients with (n=15) and without (n=15) PE. Sn-U6 and cel-miR-39 were used as reference and spike-in control respectively for data validation.

Results

A total of 184 miRNAs were identified in urinary EVs by RNA sequencing analysis whereas twenty eight miRNAs were significantly (P<0.05) changed in pregnant women with PE compared to women without PE. Selected candidates of 12miRNAs involved in renal pathophysiological processes were validated by qPCR. Among 12, only miR-143-3p remained significantly increased (P<0.018) in PE patients (both early (PE diagnosed <34 weeks) and late (>34 weeks) PE) compared to normotensive controls. The miR-95-3p was significantly decreased (P<0.048) only in patients with early PE. There was no correlation between changed miRNAs and urinary protein concentration. ROC analysis for miR-143-3p yielded an AUC of 0.776 and for miR-95-3p AUC=0.659.

Conclusion

Differential expression of miR-143-3p and miR-95-3p in urinary EVs from pregnant women with PE compared to normotensive pregnant women could be a new candidate biomarker for preeclampsia.